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Primary cardiac lymphoma (PCL) is a rare disease entity that can present with severe cardiac and cardioembolic symptoms. We
present a 79-year-old male with history of polymalgia rheumatica on chronic prednisone who presented with a two-week
history of progressively worsening dyspnea, cough, and a 10 pound weight loss. Transthoracic echocardiogram (TTE) and
computed tomography (CT) of the chest showed a large mediastinal mass with invasion of the pericardium. A biopsy of an
abdominal soft-tissue mass conﬁrmed the diagnosis of PCL. 'e patient was treated with two cycles of rituximab plus cy-
clophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) which was complicated by progressive heart failure
requiring substitution of liposomal doxorubicin. 'e epidemiology, presentation, diagnosis, and treatment options of PCL
are discussed.
1. Case Presentation
We present a 79-year-old male with history of polymyalgia
rheumatica on chronic prednisone who presented with
a two-week history of progressively worsening dyspnea,
cough, and a 10 pound weight loss. He initially presented to
an urgent care and had been prescribed antibiotics without
improvement in his symptoms. He returned to the urgent
care and underwent a chest X-ray, which was remarkable for
cardiomegaly. Given this ﬁnding in conjunction with his
respiratory symptoms, he was referred to the emergency
department (ED).
In the ED, a CT of the chest showed a large mediastinal
mass with invasion of the pericardium (Figure 1); a soft-
tissue mass within the right atrium; compression of the left
atrial appendage; encapsulation of the thoracic aorta and
pulmonary artery; and extensive mediastinal, hilar, and
subcarinal lymphadenopathy—the largest of which mea-
sured 3 cm in diameter. CT of the abdomen and pelvis
showed numerous intra-abdominal and retroperitoneal soft-
tissue masses.
'e patient was admitted to the intensive care unit (ICU)
where a TTE showed a left ventricular ejection fracture of
55% along with a large, homogenous adherent mass in-
ﬁltrating the right atrium and ventricle, abnormal thick-
ening of the interatrial and interventricular septum of the
right heart, severe right ventricular dysfunction, severe basal
to apical hypokinesis to akinesis, and a pulmonary artery
pressure of 21.8mmHg (Figures 2 and 3).
Initial diﬀerential included primary lymphoma, cardiac
sarcoma, or metastatic involvement of the heart. 'e patient
underwent a biopsy of an abdominal soft-tissue mass. Pa-
thology showed diﬀuse large B-cell lymphoma (DLBCL),
nongerminal center type, with BCL2 and MYC.
'e patient received intravenous (IV) methylpredniso-
lone 250mg daily for ﬁve days for debulking. He was initially
treated with two cycles of R-CHOP; however, given his
persistently reduced ejection fraction, the patient was
changed to liposomal doxorubicin (R-CDOP) for the third
and fourth cycle. Furthermore, his ﬁrst cycle was also
complicated by new onset ﬁrst-degree atrioventricular block
and a right bundle branch block. A positron emission to-
mography (PET)/CT scan and TTE were scheduled prior to
the next cycle of R-CDOP. In addition to his systemic
chemotherapy, the patient received three cycles of central
nervous system prophylaxis with high-dose methotrexate.
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2. Discussion
Malignancy of the heart is most often secondary to meta-
static disease or direct invasion. Lymphoma, leukemia, and
melanoma are the most frequent primaries that metastasize
to the heart [1]. Primary cardiac tumors on the contrary are
rare—200 were found in an autopsy series of 1,000,000
patients [2]. Within primary cardiac tumors, benign tumors
are far more common than malignant tumors [3]. 'e most
common benign cardiac tumors include myxoma, papillary
ﬁbroelastoma, and lipoma—these tumors account for almost
75% of all primary cardiac tumors. Malignant primary
cardiac tumors are far less common and are primarily
sarcomas. Far more rare malignant primary tumors include
paragangliomas, extramedullary plasmacytomas, and pri-
mary lymphomas [1].
'e World Health Organization (WHO) deﬁnes PCL as
a lymphoma involving only the heart/pericardium or
a lymphoma with the bulk of the tumor in the heart in the
setting of clinical cardiac symptoms [4]. PCL accounts for
1.3% of primary cardiac tumors and 0.5% of extranodal
lymphomas. Cardiac lymphoma can be either Hodgkin or
non-Hodgkin B-cell lymphoma but are most commonly
DLBCL. PCL is more common in the immunosuppressed
patient (AIDS, post-transplant) secondary to Epstein–Barr
virus-related lymphoproliferation [5].
Primary cardiac tumors including PCL do not have
a pathognomonic presentation, rather they present based on
(a) (b)
Figure 1: Computed tomography chest with pulmonary embolism protocol. (a) Transverse view and (b) coronal view. In the transverse
view, there is extensive involvement of the anterior portion of the cardiac tissue and that encases the right atrium, right ventricle, and the
great vessels (∗). 'ere is evidence of ﬁlling defect in both the transverse and coronal views of the right atrium and ventricle, which suggests
that the surrounding mass has inﬁltrated transmurally. 'e coronal view demonstrates how extensive the invasion is likely from an anterior
to posterior approach. 'ere is also extensive thickening of the transeptal and free wall.
Figure 2: Transthoracic echo—parasternal long axis view. 'e
cardiac cycle is in systole and the right ventricle fails to have
concentric contraction demonstrated by the loss of curvature in the
posterior right ventricle (∗). 'is indicates severe right ventricle
dysfunction with severe hypokinesis/akinesis in the basal to apical
wall due to inﬁltration. 'e cardiac tissue overall lacks any sig-
niﬁcant involvement of the posterior walls given the normal left
atrium and left ventricle.
Figure 3: Transthoracic echo—parasternal short view. 'ere is
extensive homogenous echodense mass superiorly (S) and anteriorly
(A) in relation to the cardiac tissue. 'e most striking feature is that
despite the inﬁltration and surrounding of the cardiac structures of
the right atrium, right ventricle, and the aortic valve, there is no
evidence of tamponade physiology. 'e homogenous echodensity
encases the ascending aorta at the level of the aortic valve (∗),
masking the coronary ostia leading into the coronary arteries.
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their location in the heart. Right-sided tumors present with
signs and symptoms of right-sided heart failure if they are
obstructing blood ﬂow, or they can present with symptoms
of pulmonary emboli from embolic tumor fragments into
the lungs. Left-sided tumors can present with signs and
symptoms of left-sided heart failure if they are obstructing
blood ﬂow, or they can present as an ischemic stroke from
embolic tumor into the CNS. Lastly, left ventricular tumors
that are intramural can present with arrhythmias or con-
duction defects. An institutional study at the Mayo Clinic
found the most common patient complaint on presentation
to be dyspnea on exertion (79%) followed by nonspeciﬁc
chest pain (38%) and cough (21%) [6].
'e diagnosis of primary cardiac tumors is based upon
imaging and biopsy ﬁndings. TTE is often the initial image
modality but is limited by operator-expertise and body
habitus. CT of the chest can be used but is limited in soft-
tissue contrast. Cardiac magnetic resonance imaging (MRI)
is the preferred imaging modality, as it provides an un-
restricted view, high temporal resolution, and good soft-
tissue contrast to help characterize a cardiac mass. In PCL,
the tumor often appears as a large nodular mass that is
isoattenuating to myocardium on CT, isointense to myo-
cardium on T1, and hyperintense to myocardium on T2 [7].
Imaging often greatly helps characterize the type of
primary cardiac tumor. Often the diﬀerentiation between
benign and malignant or even the speciﬁc disease diagnosis
can be made based upon imaging alone. Depending on the
imaging and suspected etiology of malignancy, tissue
sampling may or may not be warranted. If imaging cannot
characterize the mass, a discussion of the risks and beneﬁts
of an invasive biopsy must take place. Methods of obtaining
a tissue diagnosis include myocardial biopsy during ex-
ploratory thoracotomy, pericardiocentesis if pericardial ef-
fusion present, TEE-guided biopsy, mediastinoscopy, and
endomyocardial transvenous biopsy [8]. In our case, it was
imperative to obtain a tissue diagnosis with malignant
cardiac tumor on the diﬀerential. Tissue was obtained from
an abdominal mass, which had a lower complication rate
than the procedures listed above.
Primary cardiac tumors are treated diﬀerently based on
the speciﬁc pathologic disease. 'ere is no gold standard of
treatment for PCL. In reported cases, anthracycline-based
chemotherapy and rituximab was associated with pro-
longed survival [9, 10]. 'ere is a limited role for surgery in
PCL, unlike many other cardiac tumors. 'ere is utility in
surgical resection if the tumor causes life-threatening he-
modynamic compromise; however, there is no evidence of
prolonged survival with surgery alone or combined with
chemotherapy in a hemodynamically stable patient [11]. It
is unclear based on a small number of cases whether ra-
diotherapy combined with chemotherapy is superior to
chemotherapy alone; furthermore, the risk of cardiopul-
monary radiation-induced injury makes it a less preferred
treatment modality [9, 10, 12]. 'e median survival ranges
from 1.5–26.5 months [13]. Our patient was treated with
two cycles of R-CHOP which was complicated by pro-
gressive heart failure requiring substitution of liposomal
doxorubicin.
3. Conclusion
In conclusion, PCL is a rare disease that accounts for 1.3% of
primary cardiac tumors and 0.5% of extranodal lymphomas.
'e disease does not have a pathognomonic presentation,
rather it presents based on its location in the heart with signs
of heart failure or cardioembolic phenomena. PCL is di-
agnosed based on imaging and tissue biopsy. If there is a high
suspicion for PCL based on imaging, it is important to obtain
a tissue biopsy. Deﬁnitive tissue diagnosis of PCL can then be
treated with anthracycline-based chemotherapy plus ritux-
imab, which has been associated with prolonged survival.
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